Bayer AG

Oncology and Molecularly Targeted Cancer Care

Non-small cell lung cancer, solid tumors, and prostate cancer are prominent areas of interest, including disease settings defined by EGFR, HER2, NTRK fusion, KRAS G12C, and MTAP deletion. Research also extends to hepatocellular carcinoma and metastatic disease.

  • Advanced solid tumors
  • HER2-mutated cancers
  • Metastatic castration-resistant prostate cancer
  • NTRK-fusion malignancies

Interest includes both precision oncology and treatment strategies for advanced, refractory, and biomarker-defined cancers.

Cardiovascular, Thrombotic, and Hemostatic Disorders

The sponsor is active in atrial fibrillation, ischemic stroke, transient ischemic attack, deep vein thrombosis, and thromboembolic events, along with coronary artery disease and cardiac arrhythmia. Studies also cover coagulopathy and hemophilia A.

  • Stroke prevention
  • Atrial fibrillation
  • Thrombosis and clot lysis
  • Hemophilia A

Additional cardiovascular work includes vasodilatory shock, arterial hypertension, and heart failure across adult and pediatric populations.

Kidney Disease and Cardiorenal Syndromes

Research activity includes chronic kidney disease, proteinuria, Alport syndrome, and kidney involvement in type 1 diabetes mellitus and type 2 diabetes mellitus. The portfolio also addresses heart failure with reduced ejection fraction and left ventricular systolic dysfunction in cardiorenal disease.

  • Chronic kidney disease
  • Alport syndrome
  • Proteinuria
  • Heart failure with kidney involvement

There is also interest in pediatric chronic kidney disease and renal complications associated with inherited and metabolic disorders.

Ophthalmology and Retinal Vascular Disease

The sponsor supports studies in diabetic macular edema, neovascular age-related macular degeneration, and macular edema secondary to retinal vein occlusion. Pediatric eye disease is also represented through retinopathy of prematurity.

  • Diabetic macular edema
  • Neovascular age-related macular degeneration
  • Retinal vein occlusion
  • Retinopathy of prematurity

Imaging-related work includes contrast-enhanced magnetic resonance imaging for central nervous system and non-central nervous system assessment.

Pulmonary Vascular Disease, Menopause, and Infectious Disease

Additional research spans pulmonary arterial hypertension, pulmonary hypertension due to left heart disease, and pulmonary hypertension associated with interstitial lung disease. The portfolio also includes vasomotor symptoms and sleep disturbances associated with menopause.

  • Pulmonary hypertension
  • Menopausal vasomotor symptoms
  • Sleep disturbances in menopause
  • Onchocerciasis

In infectious disease, the sponsor is involved in studies on onchocerciasis and soil-transmitted helminth infection, reflecting interest in parasitic disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on How Elinzanetant Affects Dabigatran Etexilate in Healthy Volunteers with Vasomotor Symptoms

    Not recruiting

    1 1 1 1
    Germany
  • Study on the Effectiveness and Safety of Finerenone for Patients with Chronic Kidney Disease and Type 1 Diabetes

    Not recruiting

    3 1
    Investigated drugs:
    Denmark Germany Italy Spain
  • Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Greece Italy Portugal Slovakia Spain +1
  • Study on Aflibercept for Adults with Diabetic Macular Edema or Wet Age-Related Macular Degeneration

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Czechia Hungary Slovakia
  • Study Comparing Radium-223 Dichloride with Abiraterone Acetate, Enzalutamide, and Prednisone in Patients with Advanced Prostate Cancer Spread to the Bone

    Not recruiting

    3 1 1 1
    Austria Czechia Finland France Germany Hungary +4
  • Continued Regorafenib Treatment for Patients with Solid Tumors from Previous Bayer Studies

    Not recruiting

    2 1 1
    Investigated drugs:
    France Spain